These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33847688)

  • 21. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
    Zdzalik D; Dymek B; Grygielewicz P; Gunerka P; Bujak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):589-98. PubMed ID: 24509625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
    Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
    Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series.
    Ruf S; Hebart H; Hjalgrim LL; Kabickova E; Lang P; Steinbach D; Schwabe GC; Woessmann W
    Pediatr Blood Cancer; 2018 Jun; 65(6):e27003. PubMed ID: 29512859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
    Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
    Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review.
    Noguchi K; Ikawa Y
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
    Lowe EJ; Reilly AF; Lim MS; Gross TG; Saguilig L; Barkauskas DA; Wu R; Alexander S; Bollard CM
    Blood; 2021 Jul; 137(26):3595-3603. PubMed ID: 33684925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refractory Anaplastic Large Cell Lymphoma Rescued by the Combination of the Second-Generation ALK Inhibitor Brigatinib, High-dose Chemotherapy and Allogeneic Stem Cell Transplantation: A Case Report and Review of the Literature.
    Caddeo G; Tecchio C; Chinello M; Balter R; Zaccaron A; Vitale V; Pezzella V; Bonetti E; Pillon M; Carraro E; Mussolin L; Cesaro S
    Clin Hematol Int; 2023 Jun; 5(2-3):130-138. PubMed ID: 37072555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ; Everett E; Zhang X; Nagaraj G
    Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
    Zhou C; Kim SW; Reungwetwattana T; Zhou J; Zhang Y; He J; Yang JJ; Cheng Y; Lee SH; Bu L; Xu T; Yang L; Wang C; Liu T; Morcos PN; Lu Y; Zhang L
    Lancet Respir Med; 2019 May; 7(5):437-446. PubMed ID: 30981696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
    Mossé YP; Voss SD; Lim MS; Rolland D; Minard CG; Fox E; Adamson P; Wilner K; Blaney SM; Weigel BJ
    J Clin Oncol; 2017 Oct; 35(28):3215-3221. PubMed ID: 28787259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
    Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
    Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful allogeneic stem cell transplantation for an adult with refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Chen CH; Chen SW; Shen WL; Chen TY; Tsao CJ; Huang WT
    Int J Hematol; 2007 Feb; 85(2):105-7. PubMed ID: 17321986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin.
    Nakai R; Fukuhara S; Maeshima AM; Kim SW; Ito Y; Hatta S; Suzuki T; Yuda S; Makita S; Munakata W; Suzuki T; Maruyama D; Izutsu K
    Clin Case Rep; 2019 Dec; 7(12):2500-2504. PubMed ID: 31893088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
    Popat S; Liu G; Lu S; Song G; Ma X; Yang JC
    Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.
    Lin HM; Pan X; Hou P; Huang H; Wu Y; Ren K; Jahanzeb M
    J Med Econ; 2020 Aug; 23(8):894-901. PubMed ID: 32347754
    [No Abstract]   [Full Text] [Related]  

  • 36. [Spontaneous remission of relapsed skin lesions of ALK-positive anaplastic large cell lymphoma after autologous stem cell transplantation].
    Yamazaki R; Koda Y; Abe R; Sakurai M; Kikuchi T; Kato J; Ouchi T; Mikami S; Mori T
    Rinsho Ketsueki; 2021; 62(1):25-29. PubMed ID: 33551421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Successful allogeneic bone marrow transplantation with reduced intensity conditioning regimen for a pediatric relapsed ALK positive anaplastic large cell lymphoma].
    Hayase T; Niijima H; Tanaka D; Wada S; Kawahara Y; Oh Y; Morimoto A
    Rinsho Ketsueki; 2016 Jul; 57(7):859-63. PubMed ID: 27498729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population modeling analyses of crizotinib in pediatric patients with ALK-positive advanced cancers.
    Jerry L; Swan L; Dana N; Balis FM; Greengard E; Huiping X
    Pediatr Blood Cancer; 2024 Sep; 71(9):e31139. PubMed ID: 38867367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients.
    Groenland SL; Geel DR; Janssen JM; de Vries N; Rosing H; Beijnen JH; Burgers JA; Smit EF; Huitema ADR; Steeghs N
    Clin Pharmacol Ther; 2021 Feb; 109(2):394-402. PubMed ID: 32686074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
    Katayama R; Friboulet L; Koike S; Lockerman EL; Khan TM; Gainor JF; Iafrate AJ; Takeuchi K; Taiji M; Okuno Y; Fujita N; Engelman JA; Shaw AT
    Clin Cancer Res; 2014 Nov; 20(22):5686-96. PubMed ID: 25228534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.